ライフサイエンスコーパス: ADP-ribose

1 XRCC1, requiring a minimum chain length of 7 ADP-ribose units in the oligo(ADP-ribose) ligand for a s

2 Sir2, Sir3, Sir4, nucleosomes, and O-acetyl-ADP-ribose.

3 ification motif where lysine can serve as an ADP-ribose acceptor site.

4 in from hepatitis E virus (HEV) serves as an ADP-ribose-protein hydrolase for mono-ADP-ribose (MAR) a

5 -oxadiazole analog in complex with Sirt2 and ADP-ribose reveals its orientation in a still unexplored

6 tor 1 (HPF1) is required for PARP1 to attach ADP-ribose groups onto the hydroxyl oxygen of the Ser re

7 t cleave the glycosidic bonds either between ADP-ribose units or between the protein proximal ADP-rib

8 arily conserved structural domains that bind ADP-ribose derivatives and are found in proteins with di

9 TRPM2 is activated by ADP ribose (ADPR) binding to its C-terminal cytosolic NU

10 deletion of Parp1 rescued normal cerebellar ADP-ribose levels and reduced the loss of cerebellar neu

11 recipitation method using well-characterized ADP-ribose binding domains to provide the first genome-w

12 dix subclass in degrading protein-conjugated ADP-ribose, including both MAR and PAR.

13 like proteases (PLPs) and a highly conserved ADP-ribose-1''-phosphatase (ADRP) macrodomain.

14 oronaviruses encode a macrodomain containing ADP-ribose-1"-phosphatase (ADRP) activity within the N t

15 Cyclic ADP ribose (cADPR) is a Ca(2+)-mobilizing intracellular

16 ependent mechanism involving CD38 and cyclic ADP ribose signalling.

17 Paneth cells in the ISC niche secrete cyclic ADP ribose that triggers SIRT1 activity and mTORC1 signa

18 ne dinucleotide phosphate (NAADP) and cyclic ADP-ribose (cADPR) are Ca(2+)-mobilizing messengers impo

19 athway involving the second messenger cyclic ADP-ribose (cADPR).

20 Br-cADPr), a competitive inhibitor of cyclic ADP-ribose (cADPr) signaling that partially relieves DAM

21 ThcD) fragmentation methods when determining ADP-ribose acceptor sites within complex cellular sample

22 allowing access to products such as dimeric ADP-ribose, which has been detected but never isolated f

23 a single ADP-ribose to a target or generate ADP-ribose chains.

24 The coronavirus macrodomain has ADP-ribose-1"-phosphatase activity; however, its functio

25 CHIKV nsP3 macrodomain is able to hydrolyze ADP-ribose groups from mono(ADP-ribosyl)ated proteins.

26 (Orbitrap, FT) scans, which produced intense ADP-ribose fragmentation ions.

27 trinsic NADase activity-cleaving NAD(+) into ADP-ribose (ADPR), cyclic ADPR, and nicotinamide, with n

28 First, we show that iso-ADP-ribose (iso-ADPr), the smallest internal poly(ADP-ri

29 The fluorescently labeled ADP-ribose dimer was then utilized in a general fluoresc

30 The latter involves the synthesis of long ADP-ribose chains that have specific properties due to t

31 RNA viruses that binds to the small molecule ADP-ribose.

32 XRCC1 complex without assistance from a mono(ADP-ribose) glycohydrolase.

33 nslationally, either attached singly as mono(ADP-ribose) (MAR) or in polymeric chains as poly(ADP-rib

34 as an ADP-ribose-protein hydrolase for mono-ADP-ribose (MAR) and poly(ADP-ribose) (PAR) chain remova

35 lation refers to the addition of one or more ADP-ribose units onto proteins post-translationally.

36 We then tested the ability of NADH, ADP-ribose, and nicotinamide to inhibit these NAD(+)-dep

37 nalysis revealed that serine serves as a new ADP-ribose acceptor site across the proteome.

38 The modification of serines by molecules of ADP-ribose plays an important role in signaling that the

39 ted ARH1, the possible unbinding pathways of ADP-ribose from non-phosphorylated and phosphorylated AR

40 abolishes DNA damage-stimulated polymers of ADP-ribose (PAR) production and the PAR-dependent NF-kap

41 The enzyme synthesizes polymers of ADP-ribose from the coenzyme NAD(+) and plays multifacet

42 Ps) synthesize and bind branched polymers of ADP-ribose to acceptor proteins using NAD as a substrate

43 fy proteins with single units or polymers of ADP-ribose to regulate DNA repair.

44 d beta-peptide, which increase production of ADP-ribose (ADPR).

45 stem from the physicochemical properties of ADP-ribose, which as a post-translational modification i

46 polymeric chains (poly-ADP-ribosylation) of ADP-ribose are conjugated to proteins by ADP-ribosyltran

47 gical processes through covalent transfer of ADP-ribose from the oxidized form of nicotinamide adenin

48 catalytic fragment show that the transfer of ADP-ribose to toxin takes place by a predominantly intra

49 recognition, interpretation, and turnover of ADP-ribose (ADPr) signaling.

50 in length of 7 ADP-ribose units in the oligo(ADP-ribose) ligand for a stable interaction with XRCC1.

51 4A was more potent than ATP, ADP, NAD(+), or ADP ribose in colonic muscles.

52 P(+), coincided with formation of 2'-phospho-ADP ribose, a CD38-derived signaling molecule.

53 Maintenance therapy with olaparib, a poly ADP ribose polymerase inhibitor given post-platinum ther

54 l-cycle, apoptotic genes, caspase-3 and poly ADP ribose polymerase-1 (PARP-1) cleavage) and was rever

55 ADAMTS-4 directly cleaved and degraded poly ADP ribose polymerase-1 (a key molecule in DNA repair an

56 which corresponded with an increase in poly ADP ribose polymerase cleavage.

57 erived DNA were resistant to platin- or poly ADP ribose polymerase inhibitor-based chemotherapy.

58 Poly ADP-ribose polymerases (PARPs) catalyze massive protein

59 s end-joining DNA repair process and in poly ADP-ribose polymerase 1 activation.

60 ant channel (C1008-->A) or silencing of poly ADP-ribose polymerase in ECs of mice prevented PMN trans

61 pathways demonstrated the activation of poly ADP-ribose polymerase-dependent cell death in bok-defici

62 uitment of DNA repair factors via their poly ADP-ribose (PAR) binding domains.

63 eficient cancers are hypersensitive to Poly (ADP ribose)-polymerase (PARP) inhibitors, but can acquir

64 Poly (ADP-ribose) is synthesized at DNA single-strand breaks a

65 Poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) olaparib

66 Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as

67 Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as

68 Poly (ADP-ribose) polymerase (PARP) inhibitors have shown prom

69 Poly (ADP-ribose) polymerase (PARP) inhibitors have shown prom

70 Poly (ADP-ribose) polymerase inhibitors (PARPis) are clinicall

71 Poly (ADP-ribose) polymerase-1 (PARP1) is a highly conserved e

72 d activation of caspase-3, -7, -8, -9, poly (ADP-ribose) polymerase, and lamin A/C.

73 inhibitor, L67, in combination with a poly (ADP-ribose) polymerase inhibitor.

74 Inhibitors against poly (ADP-ribose) polymerase (PARP) are promising targeted age

75 mediated by the zinc finger domain and poly (ADP-ribose) (PAR).

76 being targeted with platinum drugs and poly (ADP-ribose) polymerase (PARP) inhibitors.

77 egulation of glucose transporter-1 and poly (ADP-ribose) polymerase cleavage while preserving tumor t

78 sensitivity to ionizing radiation and poly (ADP-ribose) polymerase inhibition.

79 urpose Data suggest that DNA damage by poly (ADP-ribose) polymerase inhibition and/or reduced vascula

80 eir breakage, and to be antagonized by poly (ADP-ribose) polymerase/RECQ1-regulated restart.

81 Inhibition of beta-catenin, poly (ADP-ribose) polymerase 1 (PARP1), or enhancer of zeste h

82 ein BIM, cleaved caspase 3 and cleaved poly (ADP-ribose) polymerase (PARP).

83 oncomitant with an increase in cleaved poly (ADP-ribose) polymerase 1 (P < 0.05), indicative of apopt

84 ed by Western blot analysis of cleaved poly (ADP-ribose) polymerase and caspase 3.

85 xpression of caspase-3, higher cleaved poly (ADP-ribose) polymerase levels (p < 0.007), and a higher

86 rpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is super

87 served in all eukaryotic cells include poly (ADP-ribose) polymerases (PARPs), sirtuins, AMP-activated

88 e-8, and caspase-9 activation and less poly (ADP-ribose) polymerase cleavage compared with WT livers

89 Rucaparib is an inhibitor of nuclear poly (ADP-ribose) polymerases (inhibition of PARP-1 > PARP-2 >

90 we have characterized the mechanism of poly (ADP-ribose) binding by XRCC1 and examined its importance

91 s were tested for inhibitory effect of poly (ADP-ribose) polymerase (PARP) activity in vitro and in v

92 apoptotic cell death and detection of poly (ADP-ribose) polymerase (PARP) cleavage.

93 ogies for studying robust responses of poly (ADP-ribose) polymerase-1 (PARP-1) to DNA damage with str

94 ctasia mutated (ATM), but dependent on poly (ADP-ribose) polymerase 1 (PARP1), which ADP ribosylates

95 ing protein 1, DNA polymerase beta, or poly (ADP-ribose) polymerase 1 activity, all of which fail to

96 Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germli

97 ely, and high selectivity toward other poly (ADP-ribose) polymerase enzymes.

98 omoting stabilization of a new target, poly (ADP-ribose) glycohydrolase (PARG) mRNA, by binding a uni

99 sub-nuclear PCNA foci, suggesting that poly (ADP-ribose) promotes XRCC1 recruitment both at single-st

100 These data support the hypothesis that poly (ADP-ribose) synthesis promotes XRCC1 recruitment at DNA

101 t approval of olaparib (Lynparza), the poly (ADP-ribose) polymerase (PARP) inhibitor for treating tum

102 Durable and long-term responses to the poly (ADP-ribose) polymerase inhibitor olaparib are observed i

103 1 is required for selective binding to poly (ADP-ribose) at low levels of ADP-ribosylation, and promo

104 y PML-RARA) are extremely sensitive to poly (ADP-ribose) polymerase (PARP) inhibition, in part owing

105 ential marker of long-term response to poly (ADP-ribose) polymerase inhibition and that restoration o

106 diotherapy, or previous treatment with poly (ADP-ribose) polymerase inhibitors.

107 Poly [ADP-ribose] polymerase 1 (PARP-1) is a highly abundant c

108 posomes were used to deliver a PARP-1 (poly [ADP-ribose] polymerase 1) inhibitor: AZ7379.

109 alpha-ketoglutarate or treatment with a poly(ADP ribose) polymerase inhibitor protects reductive carb

110 nd cleavage of caspases 3, 8, and 9 and poly(ADP ribose) polymerase, and suppressed survivin, myeloid

111 , mtp53 depletion profoundly influenced poly(ADP ribose) polymerase 1 (PARP1) localization, with incr

112 nd -3 that, in turn, led to cleavage of poly(ADP ribose) polymerase and Mcl-1.

113 Ca(2+) and Na(+) influx, activation of poly(ADP ribose) polymerase-1 (PARP-1), and delayed Ca(2+) de

114 g parthanatos, monitored by cleavage of poly(ADP ribose)polymerase-1 (PARP-1), or necroptosis, assess

115 of the topoisomerase IIbeta (TOP2beta)/poly(ADP ribose) polymerase 1 (PARP1) complex are necessary f

116 Poly(ADP-ribose) (PAR) is a posttranslational modification pr

117 Poly(ADP-ribose) (PAR) polymerase 1 (PARP1) catalyzes the pol

118 Poly(ADP-ribose) polymerase (PARP) inhibitors have activity i

119 Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors were recentl

120 Poly(ADP-ribose) polymerase-1 (PARP-1) creates the posttransl

121 Poly(ADP-ribose) polymerase-1 (PARP-1) is an abundant nuclear

122 Poly(ADP-ribose) polymerase-2 (PARP-2) is one of three human

123 Poly(ADP-ribose) polymerases (PARPs) are involved in DNA repa

124 Poly(ADP-ribose) polymerases (PARPs) synthesize and bind bran

125 Poly(ADP-ribose) polymerases (PARPs), enzymes that modify tar

126 Poly(ADP-ribose)polymerase 1 (PARP-1) is a key eukaryotic str

127 uced cleavage of caspase-3, -8, and -9, poly(ADP-ribose) polymerase, and the externalization of phosp

128 equired for DNA repair that possesses a poly(ADP-ribose) (PAR)-binding macro domain.

129 We report results for veliparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, combined with c

130 Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has previously

131 colorectal cancer by interacting with a poly(ADP-ribose) polymerase (PARP) tankyrase.

132 provides further evidence that use of a poly(ADP-ribose) polymerase inhibitor in the maintenance trea

133 Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activit

134 ent of the chemotherapeutic Olaparib, a poly(ADP-ribose) polymerase inhibitor, in live cells and with

135 had received previous treatment with a poly(ADP-ribose) polymerase inhibitor.

136 nses through its N-terminal region in a poly(ADP-ribose) polymerase-dependent manner.

137 al pharmaceutical target tankyrase 1, a poly(ADP-ribose) polymerase.

138 demonstrate the involvement of Alc1, a poly(ADP-ribose)- and ATP-dependent remodeler, in the chromat

139 he difficulty associated with accessing poly(ADP-ribose) (PAR) in a homogeneous form has been an impe

140 controls gene expression by activating poly(ADP-ribose) polymerase-1 (PARP-1).

141 Conversely, PARPs, which add poly(ADP-ribose) to proteins, inhibit axon regeneration of bo

142 hydrolase for mono-ADP-ribose (MAR) and poly(ADP-ribose) (PAR) chain removal (de-MARylation and de-PA

143 -1 overexpression stimulates PARP-1 and poly(ADP-ribose) (PAR) protein expression and cisplatin resis

144 cellular sensitization to radiation and poly(ADP-ribose) polymerase (PARP) inhibition.

145 geneous responses to platinum drugs and poly(ADP-ribose) polymerase (PARP) inhibitors in clinical tri

146 tumors to DNA cross-linking agents and poly(ADP-ribose) polymerase (PARP) inhibitors, we sought to i

147 amaging agents, including cisplatin and poly(ADP-ribose) polymerase (PARP) inhibitors.

148 ROS and poly(ADP-ribose) polymerase also reduce sirtuin, PGC-1alpha,

149 initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; howeve

150 ADP-ribose) glycohodrolases (PARGs) and poly(ADP-ribose) polymerases (PARPs).

151 enzyme families, including sirtuins and poly(ADP-ribose) polymerases.

152 erization with Parp9 enables NAD(+) and poly(ADP-ribose) regulation of E3 activity.

153 nic/apyrimidinic endonuclease 1 (APE1), poly(ADP-ribose) polymerase 1 (PARP1), X-ray repair cross-com

154 Tankyrase 1 and 2 are poly(ADP-ribose) polymerases that function in pathways critic

155 ribose) (MAR) or in polymeric chains as poly(ADP-ribose) (PAR).

156 ies of tetrahydropyridophthlazinones as poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitors.

157 a), which under oxidative stress become poly(ADP-ribose)lated (PARylated).

158 jacent WWE domain that is known to bind poly(ADP-ribose) chains.

159 Following DNA double-strand breaks, poly(ADP-ribose) (PAR) is quickly and heavily synthesized to

160 reaks and disruption of this pathway by Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) is toxi

161 ADP-ribosyl)ation mediated primarily by poly(ADP-ribose) polymerase 1 (PARP1) is responsible for the

162 se (PAR) chains, primarily catalyzed by poly(ADP-ribose) polymerase 1 (PARP1), is crucial for cellula

163 ADP-ribose) (PAR) is mediated mainly by poly(ADP-ribose) polymerase 1 (PARP1).

164 dification, is immediately catalyzed by poly(ADP-ribose) polymerases (PARPs) at DNA lesions, which fa

165 translational modification catalyzed by poly(ADP-ribose) polymerases (PARPs) that mediate EBV replica

166 spase-3, cleaved caspase-7, and cleaved poly(ADP-ribose) polymerase (PARP).

167 ted by caspase-3/7 activity and cleaved poly(ADP-ribose) polymerase, in different cell lines that sup

168 he SNAT2 ER-alpha-ERE complex contained poly(ADP-ribose) polymerase 1, Lupus Ku autoantigen protein p

169 Increasing evidence define Poly(ADP-ribose) polymerase 3 (PARP3, also known as ARTD3) as

170 omatin condensation as well as distinct poly(ADP-ribose)polymerase-1 cleavage.

171 inhibition of the NAD-consuming enzyme poly(ADP-ribose) polymerase (PARP)-1 or supplementation with

172 The nuclear enzyme poly(ADP-ribose) polymerase 1 (PARP1) has been shown to facil

173 ological activity of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP1) causes neuron death in

174 The enzyme poly(ADP-ribose)polymerase (PARP) has a dual function being i

175 we demonstrate that the nuclear enzyme Poly(ADP-ribose)Polymerase 1 (PARP1) is a promising target fo

176 k we identify a physical and functional poly(ADP-ribose)-mediated interaction of PARP1 with the E3 ub

177 clear LXRalpha complexes and identified poly(ADP-ribose) polymerase-1 (PARP-1) as an LXR-associated f

178 Here, we identify poly(ADP-ribose) polymerase 1 (PARP1) as a previously unident

179 chromatin accumulation was enhanced in poly(ADP-ribose) polymerase (PARP) 1(-/-) compared with wild-

180 drugs that block DNA repair, including poly(ADP-ribose) polymerase (PARP) inhibitors, fail due to la

181 and BCBL1 PEL cells but did not induce poly(ADP-ribose) polymerase (PARP) cleavage in virus-negative

182 we show that the loss of TCDD-inducible poly(ADP-ribose) polymerase (Tiparp), an ADP-ribosyltransfera

183 epressor (Ahrr/AhRR) and TCDD-inducible poly(ADP-ribose)polymerase (Tiparp/TiPARP) by AhR ligands wer

184 Interestingly, miR-149 inhibits poly(ADP-ribose) polymerase-2 (PARP-2) and so increased cellu

185 cells and decreases the level of intact poly(ADP-ribose) polymerase, which is indicative of apoptosis

186 ibose (iso-ADPr), the smallest internal poly(ADP-ribose) (PAR) structural unit, binds between the WWE

187 The mammalian poly(ADP-ribose) polymerase (PARP) family includes ADP-ribosy

188 -2 and IL-1beta) and apoptotic markers (poly(ADP-ribose) polymerase (PARP) and caspase 3).

189 repeat-containing protein that mediates poly(ADP-ribose) polymerase-1 (PARP-1)-dependent transcriptio

190 tigated the regulation of mitochondrial poly(ADP-ribose) polymerase 1 (PARP1) by the cyclic adenosine

191 n of the posttranslational modification poly(ADP-ribose) (PAR) to facilitate repair.

192 Moreover, poly(ADP-ribose) binding to the Parp9 macrodomains increases

193 This activates nuclear poly(ADP-ribose) polymerase, which inhibits GAPDH, shunting e

194 The discovery of poly(ADP-ribose) >50 years ago opened a new field, leading th

195 DNA damage response by the synthesis of poly(ADP-ribose) (PAR) is mediated mainly by poly(ADP-ribose)

196 Inhibition or genetic deletion of poly(ADP-ribose) (PAR) polymerase-1 (PARP-1) is protective ag

197 Over 50 years ago, the discovery of poly(ADP-ribose) (PAR) set a new field of science in motion-t

198 PARP1, resulting in the accumulation of poly(ADP-ribose) in the cell body and axon and limited axonal

199 Our results indicate that regulation of poly(ADP-ribose) levels is a critical function of the DLK reg

200 ide insight into why clinical trials of poly(ADP-ribose) polymerase (PARP) inhibitors, which require

201 This study explores the role of poly(ADP-ribose) polymerase (PARP) on global gene expression

202 dependent auto-poly-ADP-ribosylation of poly(ADP-ribose) polymerase 1 (PARP1).

203 eton while promoting the degradation of poly(ADP-ribose) polymerase 1, an inhibitor of osteoclastogen

204 uding HMGN1 and RFC1; and regulation of poly(ADP-ribose) polymerase activity.

205 conditions correlates with cleavage of poly(ADP-ribose) polymerase, an indicator of apoptosis.

206 rn blotting for the cleaved fragment of poly(ADP-ribose) polymerase, and the active isoform of caspas

207 mages DNA and causes hyperactivation of poly(ADP-ribose) polymerase, resulting in extensive NAD(+)/AT

208 This work focuses on the regulation of poly(ADP-ribose) polymerase-1 (PARP-1) expression by MKP-1.

209 Interest in nuclear imaging of poly(ADP-ribose) polymerase-1 (PARP-1) has grown in recent ye

210 uman cells to olaparib, an inhibitor of poly(ADP-ribose) polymerase.

211 PNKP and implicates hyperactivation of poly(ADP-ribose) polymerase/s as a cause of cerebellar ataxia

212 l the mechanisms by which inhibition of poly(ADP-ribose) polymerases (PARPs) elicits clinical benefit

213 ng to the tankyrase (Tnks) subfamily of poly(ADP-ribose) polymerases (PARPs) have recently been shown

214 ecursors, exercise regimens, or loss of poly(ADP-ribose) polymerases yet surprisingly do not exhibit

215 A burst of poly(ADP-ribose) synthesis initiates DNA damage response, whe

216 not find that histone H1 accumulated on poly(ADP-ribose) (PAR) in vivo.

217 n identifying ADP-ribosylation sites on Poly(ADP-ribose) Polymerase 1 (PARP1) with mass spectrometry

218 Veliparib, an oral poly(ADP-ribose) polymerase inhibitor, has been shown to enha

219 endonuclease in cooperation with PARP1 poly(ADP-ribose) polymerase and RPA The novel gap formation s

220 we show that the anti-apoptotic protein poly(ADP-ribose) polymerase (PARP)14 promotes aerobic glycoly

221 The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established

222 rinsic regulators of axon regeneration: poly(ADP-ribose) glycohodrolases (PARGs) and poly(ADP-ribose)

223 PARGs, which remove poly(ADP-ribose) from proteins, act in injured C. elegans GAB

224 and cleavage of the caspase 3 substrate poly(ADP-ribose) polymerase were inhibited in E. faecalis-inf

225 of enzymes consume NAD(+) as substrate: poly(ADP-ribose) polymerases, ADP-ribosyl cyclases (CD38 and

226 This was linked to suppressed poly(ADP-ribose) polymerase-1 activity and was reversible on

227 ors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approve

228 We found that poly(ADP-ribose) polymerase (PARP) activation distinguishes b

229 opus egg extract assays, we showed that poly(ADP-ribose) polymerase 1 (PARP1) is modified by SUMO2/3

230 Herein, we demonstrate that poly(ADP-ribose)polymerase-1 (PARP-1) is a genome-wide epigen

231 Prior work has established that the poly(ADP-ribose) polymerase (PARP) enzyme Tankyrase (TNKS) an

232 The poly(ADP-ribose) polymerase (PARP) enzymes were initially cha

233 eading the way for the discovery of the poly(ADP-ribose) polymerase (PARP) family of enzymes and the

234 Further, we observed that the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib synergi

235 ents melphalan and cisplatin and to the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-8

236 the present study we observed that the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and ve

237 The poly(ADP-ribose) polymerase (PARP) Tankyrase (TNKS and TNKS2)

238 SP1 bind to a composite element in the poly(ADP-ribose) polymerase 1 (PARP-1) promoter in a mutually

239 The poly(ADP-ribose) polymerase inhibitor olaparib has shown anti

240 Resolution at telomeres requires the poly(ADP-ribose) polymerase tankyrase 1, but the mechanism th

241 istone variant macroH2A1.1 binds to the poly(ADP-ribose) polymerase tankyrase 1, preventing it from l

242 The poly(ADP-ribose) polymerases (PARPs) are a major family of en

243 of tankyrases, which are members of the poly(ADP-ribose) polymerases (PARPs).

244 inity that depends on the length of the poly(ADP-ribose) strand and competes with DNA for protein bin

245 gets are the tankyrase proteins (TNKS), poly(ADP-ribose) polymerases (PARP) that regulate Wnt signali

246 ases the binding of the macro domain to poly(ADP-ribose) and stimulates the de-PARylation activity.

247 BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors.

248 responsible for cellular sensitivity to poly(ADP-ribose) polymerase inhibitors (PARPi) in BRCA1-defic

249 -N domain binds with higher affinity to poly(ADP-ribose) than to DNA.

250 of nuclear ATP, leading from NAD(+) to poly(ADP-ribose) to ADP-ribose to ATP, which supports the act

251 trials exploiting this concept by using poly(ADP-ribose) polymerase (PARP) inhibitors in patients wit

252 Various poly(ADP-ribose) polymerases which are notorious guardians of

253 The vault-interacting domain of vault poly(ADP-ribose)-polymerase (INT) has been used as a shuttle

254 slational modification of proteins with poly(ADP-ribose) (PAR) regulates protein-protein interactions

255 teractions of RNA-binding proteins with poly(ADP-ribose) can affect their function.

256 erstanding the interactions of PAR with poly(ADP-ribose) glycohydrolase (PARG) and other binding prot

257 ellular hyper-dependence on alternative poly-ADP ribose polymerase (PARP)-mediated DNA repair mechani

258 Assays for DNA ladder formation and poly-ADP ribose polymerase (PARP) cleavage were performed to

259 drugs, which is further exacerbated by poly-ADP ribose polymerase (PARP) inhibitors.

260 how that the latonduine analogs inhibit poly-ADP ribose polymerase (PARP) isozymes 1, 3, and 16.

261 endent polymerization of long chains of poly-ADP ribose (PAR) onto itself in response to DNA damage a

262 chilling) and more than 60% cleavage of poly-ADP ribose polymerase (compared to less than 5% in contr

263 and activation of the DNA damage sensor poly-ADP ribose polymerase 1 (PARP1).

264 ), matrix metalloproteinases (MMPs) and poly-ADP-ribose-polymerase-1 (PARP-1) in diabetic kidney remo

265 mage, PARP1 interacts with and attaches poly-ADP-ribose (PAR) chains to EZH2.

266 ion (PARylation) is mainly catalysed by poly-ADP-ribose polymerase 1 (PARP1), whose role in gene tran

267 s and is catalyzed by 11 members of the poly-ADP-ribose polymerase (PARP) family of proteins (17 in h

268 s (DSBs) and were modestly sensitive to poly-ADP-ribose polymerase (PARP) inhibitors olaparib and BMN

269 sensitizing BRCA1-deficient tumours to poly-ADP-ribose polymerase-1 (PARP) inhibitors.

270 Poly-(ADP-ribose) polymerase (PARP) inhibitors (PARPis) select

271 nd Bak, and processing of caspases and poly-(ADP-ribose) polymerase (PARP-gamma).

272 n from mitochondria to the nucleus and poly-(ADP-ribose)-polymerase (PARP) activation.

273 (PARP1) and the deribosylating enzyme poly-(ADP-ribose) glycohydrolase (PARG), which dynamically reg

274 by the nuclear ADP-ribosylating enzyme poly-(ADP-ribose) polymerase 1 (PARP1) and the deribosylating

275 imaging strategy for DLBCL that targets poly[ADP ribose] polymerase 1 (PARP1), the expression of whic

276 ), phosphorylated H2AX (gammaH2AX), and poly[ADP-ribose] polymerase 1 (PARP-1).

277 unique loop that both excludes proteinaceous ADP-ribose acceptors and contributes to hydrolysis.

278 ribose units or between the protein proximal ADP-ribose and a given amino acid side chain.

279 structure of adenosine-5-diphosphate-ribose (ADP-ribose) in complex with non-phosphorylated and phosp

280 ibosyltransferases either conjugate a single ADP-ribose to a target or generate ADP-ribose chains.

281 tivated following DNA damage and synthesizes ADP-ribose polymers that XRCC1 binds directly.

282 sor adenomatous polyposis coli (APC) and the ADP-ribose polymerase Tankyrase (Tnks) have evolutionari

283 talytic site and at distal sites, can be the ADP-ribose acceptor in the auto-reaction.

284 Nevertheless, accurate assignment of the ADP-ribose acceptor site(s) within the modified proteins

285 re we describe the chemical synthesis of the ADP-ribose dimer, and we use this compound to obtain the

286 P-ribosylation refers to the transfer of the ADP-ribose group from NAD(+) to target proteins post-tra

287 d the unique fragmentation properties of the ADP-ribose moiety were used to trigger targeted fragment

288 Inhibitors of the ADP-ribose polymerase Tankyrase (Tnks) have become lead

289 rly effects of Wnt on Axin and find that the ADP-ribose polymerase Tankyrase (Tnks)--known to target

290 he COG1058 family and is associated with the ADP-ribose pyrophosphatase activity.

291 ient binding of the MERS-CoV macro domain to ADP-ribose.

292 , leading from NAD(+) to poly(ADP-ribose) to ADP-ribose to ATP, which supports the activity of ATP-de

293 hydrolyze the nicotinamide and transfer (tz)ADP-ribose to an arginine analogue, respectively.

294 nicotinamide's glycosidic bond yielding (tz)ADP-ribose.

295 RS-CoV macro domain in the host response via ADP-ribose binding but also as a potential target for dr

296 ttranslational protein modification in which ADP-ribose is transferred from NAD(+) to specific accept

297 ermined at 1.43-A resolution in complex with ADP-ribose.

298 ters how the conserved Asp-20 interacts with ADP-ribose and may explain the efficient binding of the

299 s), enzymes that modify target proteins with ADP-ribose, play important roles in many of the RNA regu

300 tide (NAD(+)) to modify target proteins with ADP-ribose.